Johnson & Johnson (JNJ) : Peddock Capital Advisors scooped up 76 additional shares in Johnson & Johnson during the most recent quarter end , the firm said in a disclosure report filed with the SEC on Jul 15, 2016. The investment management firm now holds a total of 9,567 shares of Johnson & Johnson which is valued at $1,178,080.Johnson & Johnson makes up approximately 0.74% of Peddock Capital Advisors’s portfolio.
Other Hedge Funds, Including , Heritage Investors Management Corp reduced its stake in JNJ by selling 11,034 shares or 6.05% in the most recent quarter. The Hedge Fund company now holds 171,464 shares of JNJ which is valued at $21,114,077. Johnson & Johnson makes up approx 1.54% of Heritage Investors Management Corp’s portfolio.Lenox Wealth Advisors reduced its stake in JNJ by selling 94 shares or 9.39% in the most recent quarter. The Hedge Fund company now holds 907 shares of JNJ which is valued at $111,561. Johnson & Johnson makes up approx 0.03% of Lenox Wealth Advisors’s portfolio.Stokes Hubbell Capital Management reduced its stake in JNJ by selling 769 shares or 0.85% in the most recent quarter. The Hedge Fund company now holds 89,397 shares of JNJ which is valued at $10,982,421. Johnson & Johnson makes up approx 4.69% of Stokes Hubbell Capital Management’s portfolio.Next Financial Group Inc boosted its stake in JNJ in the latest quarter, The investment management firm added 2,238 additional shares and now holds a total of 33,178 shares of Johnson & Johnson which is valued at $4,075,917. Johnson & Johnson makes up approx 1.28% of Next Financial Group Inc’s portfolio.Cullinan Associates Inc reduced its stake in JNJ by selling 1,616 shares or 1.02% in the most recent quarter. The Hedge Fund company now holds 157,307 shares of JNJ which is valued at $19,079,766. Johnson & Johnson makes up approx 1.55% of Cullinan Associates Inc’s portfolio.
Johnson & Johnson opened for trading at $123 and hit $123.22 on the upside on Monday, eventually ending the session at $123.14, with a gain of 0.11% or 0.14 points. The heightened volatility saw the trading volume jump to 65,99,199 shares. Company has a market cap of $338,714 M.
On the company’s financial health, Johnson & Johnson reported $1.74 EPS for the quarter, beating the analyst consensus estimate by $ 0.06 according to the earnings call on Jul 19, 2016. Analyst had a consensus of $1.68. The company had revenue of $18482.00 million for the quarter, compared to analysts expectations of $17985.80 million. The company’s revenue was up 3.9% compared to the same quarter last year. During the same quarter in the previous year, the company posted $1.71 EPS.
Many Wall Street Analysts have commented on Johnson & Johnson. Standpoint Research Initiated Johnson & Johnson on May 20, 2016 to “Sell”, Price Target of the shares are set at $94.Company shares were Reiterated by RBC Capital Mkts on Apr 20, 2016 to “Outperform”, Firm has raised the Price Target to $ 125 from a previous price target of $122 .Company shares were Reiterated by Piper Jaffray on Apr 20, 2016 to “Neutral”, Firm has raised the Price Target to $ 106 from a previous price target of $105 .
Johnson & Johnson is a holding company. The Company is engaged in the research and development manufacture and sale of a range of products in the health care field. The Company has more than 265 operating companies conducting business around the world. The Companys primary focus is products related to human health and well-being. The Company is organized into three business segments: Consumer Pharmaceutical and Medical Devices. The Company’s subsidiaries operate 134 manufacturing facilities occupying approximately 21.5 million square feet of floor space. The Companys research facilities are located in the United States Belgium Brazil Canada China France Germany India Israel Japan the Netherlands Singapore Switzerland and the United Kingdom.